Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial

Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial

Background Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose of the study w...

Full description

Bibliographic Details
Main Authors: Banai, Shmuel (Author), Finkelstein, Ariel (Author), Almagor, Yaron (Author), Assali, Abid (Author), Hasin, Yonathan (Author), Rosenschein, Uri (Author), Apruzzese, Patricia (Author), Lansky, Alexandra J. (Author), Kume, Teruyoshi (Author), Edelman, Elazer R. (Contributor)
Other Authors: Harvard University- (Contributor)
Format: Article
Language:English
Published: Elsevier, 2016-05-22T18:37:09Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items